These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 35957721)

  • 21. Concurrent chemoradiotherapy with/without induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: Long-term results of phase 3 randomized controlled trial.
    Li WF; Chen NY; Zhang N; Hu GQ; Xie FY; Sun Y; Chen XZ; Li JG; Zhu XD; Hu CS; Xu XY; Chen YY; Hu WH; Guo L; Mo HY; Chen L; Mao YP; Sun R; Ai P; Liang SB; Long GX; Zheng BM; Feng XL; Gong XC; Li L; Shen CY; Xu JY; Guo Y; Chen YM; Zhang F; Lin L; Tang LL; Liu MZ; Ma J; Sun Y
    Int J Cancer; 2019 Jul; 145(1):295-305. PubMed ID: 30613964
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Which treatment is better than concurrent chemoradiotherapy about survival for stage III or IV locally advanced nasopharyngeal carcinoma? An updated Bayesian network meta-analysis of randomized controlled trials.
    Fang L; Shi L; Wang W; Hu T; Rao X
    Eur Arch Otorhinolaryngol; 2021 Oct; 278(10):3633-3642. PubMed ID: 33598731
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Induction Chemotherapy Has No Prognostic Value in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma and Chronic Hepatitis B Infection in the IMRT Era.
    Zhang LL; Zhou GQ; Li YC; Lin AH; Ma J; Qi ZY; Sun Y
    Transl Oncol; 2017 Oct; 10(5):800-805. PubMed ID: 28844018
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Induction chemotherapy with docetaxel, cisplatin and fluorouracil followed by concurrent chemoradiotherapy or chemoradiotherapy alone in locally advanced non-endemic nasopharyngeal carcinoma.
    Ou D; Blanchard P; El Khoury C; De Felice F; Even C; Levy A; Nguyen F; Janot F; Gorphe P; Deutsch E; Temam S; Tao Y
    Oral Oncol; 2016 Nov; 62():114-121. PubMed ID: 27865364
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Individualized cumulative cisplatin dose for locoregionally-advanced nasopharyngeal carcinoma patients receiving induction chemotherapy and concurrent chemoradiotherapy.
    Wen DW; Li ZX; Chen FP; Lin L; Peng BY; Kou J; Zheng WH; Yang XL; Xu SS; Sun Y; Zhou GQ
    Oral Oncol; 2020 Aug; 107():104675. PubMed ID: 32361563
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Beneficial effects of anti-EGFR agents, Cetuximab or Nimotuzumab, in combination with concurrent chemoradiotherapy in advanced nasopharyngeal carcinoma.
    Lin M; You R; Liu YP; Zhang YN; Zhang HJ; Zou X; Yang Q; Li CF; Hua YJ; Yu T; Cao JY; Li JB; Mo HY; Guo L; Lin AH; Sun Y; Qian CN; Ma J; Mai HQ; Chen MY
    Oral Oncol; 2018 May; 80():1-8. PubMed ID: 29706183
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Radiotherapy Alone Versus Concurrent or Adjuvant Chemoradiotherapy for Nasopharyngeal Carcinoma Patients with Negative Epstein-Barr Virus DNA after Induction Chemotherapy.
    Kong F; Pan G; Du C; Hu C; Ying H
    Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980576
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Induction chemotherapy followed by concurrent chemoradiotherapy vs. concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study.
    Zhang J; Chen S; Li G; Zhang W; Qin T; Yin P; Huang H; Jiang H
    Cancer Chemother Pharmacol; 2017 Jun; 79(6):1087-1097. PubMed ID: 28429051
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Stage-specific concurrent chemoradiotherapy with or without induction chemotherapy for locoregionally advanced nasopharyngeal carcinoma: a retrospective, population-based study.
    Xia WX; Liang H; Lv X; Wang L; Ye YF; Ke LR; Xu LH; Guo X; Xiang YQ
    Cancer Manag Res; 2019; 11():9813-9827. PubMed ID: 31819619
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Individualized induction chemotherapy by pre-treatment plasma Epstein-Barr viral DNA in advanced nasopharyngeal carcinoma.
    Zhang J; Peng H; Li WF; Zhang Y; Liu LZ; Tian L; Lin AH; Sun Y; Ma J
    BMC Cancer; 2018 Dec; 18(1):1276. PubMed ID: 30567511
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The evaluation of adding induction chemotherapy to concurrent chemoradiotherapy for locally advanced nasopharyngeal carcinoma: a meta-analysis.
    Tang M; Jia Z; Zhang J
    Eur Arch Otorhinolaryngol; 2021 May; 278(5):1545-1558. PubMed ID: 32700235
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Survival benefit of induction chemotherapy for locally advanced nasopharyngeal carcinoma: prognosis based on a new risk estimation model.
    Liu W; Yu B; Luo Y; Li J; Yuan X; Wu S; Liang B; Lv Z; Li Y; Peng X; Lu J; Peng X; Liu X
    BMC Cancer; 2021 May; 21(1):639. PubMed ID: 34051750
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical value of docetaxel plus cisplatin (TP) induction chemotherapy followed by TP concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma.
    Tao HY; Zhan ZJ; Qiu WZ; Liao K; Yuan YW; Yuan TZ; Zheng RH
    J Cancer; 2021; 12(1):18-27. PubMed ID: 33391399
    [No Abstract]   [Full Text] [Related]  

  • 34. Prognostic value of chronic hepatitis B virus infection in patients with nasopharyngeal carcinoma: analysis of 1301 patients from an endemic area in China.
    Liu X; Li X; Jiang N; Lei Y; Tang LL; Chen L; Zhou GQ; Sun Y; Yue D; Guo R; Mao YP; Li WF; Liu LZ; Tian L; Lin AH; Ma J
    Cancer; 2014 Jan; 120(1):68-76. PubMed ID: 24114075
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Induction chemotherapy followed by radiotherapy
    Liu LT; Liang YJ; Guo SS; Mo HY; Guo L; Wen YF; Xie HJ; Tang QN; Sun XS; Liu SL; Li XY; Yang JH; Yang ZC; Tang LQ; Chen QY; Mai HQ
    Ther Adv Med Oncol; 2020; 12():1758835920928214. PubMed ID: 32536983
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Concurrent Chemoradiotherapy With or Without Induction Chemotherapy for Patients with Stage II Nasopharyngeal Carcinoma: An Update.
    Jin T; Zhang Q; Luo DH; Jiang F; Jin QF; Chen YY; Chen XZ; Mao WM
    Transl Oncol; 2020 Jan; 13(1):25-31. PubMed ID: 31743830
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of adjuvant chemotherapy on survival in patients with residual nasopharyngeal carcinoma after undergoing concurrent chemoradiotherapy.
    Yang S; Lin S; Fu Q; Cai B; Kong F; Huang G; Li F; Wang H
    PLoS One; 2015; 10(3):e0120019. PubMed ID: 25799566
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Survival benefit of induction chemotherapy in treatment for stage III or IV locally advanced nasopharyngeal carcinoma - An updated meta-analysis and systematic review.
    Hu T; Fang L; Shi L; Wang W; Huang Y
    Am J Otolaryngol; 2021; 42(5):102973. PubMed ID: 33812206
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Optimal cumulative cisplatin dose in nasopharyngeal carcinoma patients based on induction chemotherapy response.
    Liu SL; Sun XS; Yan JJ; Chen QY; Lin HX; Wen YF; Guo SS; Liu LT; Xie HJ; Tang QN; Liang YJ; Li XY; Lin C; Du YY; Yang ZC; Xiao BB; Yang JH; Tang LQ; Guo L; Mai HQ
    Radiother Oncol; 2019 Aug; 137():83-94. PubMed ID: 31078941
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Induction chemotherapy followed by concurrent chemoradiotherapy is benefit for advanced stage nasopharyngeal carcinoma with different nonkeratinizing carcinoma subtypes.
    Zang J; Li C; Xu M; Xu W; Kang X; Wang J; Luo S; Shi M
    Sci Rep; 2018 Sep; 8(1):13318. PubMed ID: 30190563
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.